tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Arthritis, Experimental D001169 24 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Brain Diseases D001927 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Endotoxemia D019446 27 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Obesity D009765 29 associated lipids
Kidney Diseases D007674 29 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Catalepsy D002375 30 associated lipids
Dermatitis D003872 30 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Loinaz C et al. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. 2001 Nov-Dec Transplant. Proc. pmid:11750472
Tolba RH et al. Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life. 2001 Nov-Dec Transplant. Proc. pmid:11750475
Rostaing L et al. Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. 1998 Transplant. Proc. pmid:9636519
Rostaing L et al. Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. 1998 Transplant. Proc. pmid:9636520
Hu RH et al. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. 2000 Transplant. Proc. pmid:11119894
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Kinoshita I et al. Immunosuppression with FK 506 insures good success of myoblast transplantation in MDX mice. 1994 Transplant. Proc. pmid:7527978
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Reggiani P et al. Conversion to rescue therapy with FK 506: data from eight liver transplant patients. 1994 Transplant. Proc. pmid:7527982
Porayko MK et al. Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. 1993 Transplant. Proc. pmid:7679835
Iwasaki K et al. Pharmacokinetic study of FK 506 in the rat. 1991 Transplant. Proc. pmid:1721268
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Takada S et al. HGF prevents tacrolimus (FK 506)-induced nephrotoxicity in SHR rats. 1996 Transplant. Proc. pmid:8623236
Murase N et al. Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. 1990 Transplant. Proc. pmid:1689906
Qu W et al. Correlation Between Immunosuppressive Therapy and CD4(+) T-Cell Intracellular Adenosine Triphosphate Levels in Liver Transplant Recipients. Transplant. Proc. pmid:27569951
Steinmueller T et al. Effect of CsA versus FK 506 on insulin sensitivity and insulin response using a modeling technique. 1998 Transplant. Proc. pmid:9636589
Miura S et al. The beneficial effects of FK 506 on living-related renal transplantation in presensitized recipients. 1999 Transplant. Proc. pmid:10455940
Hossain MA et al. Effect of the immunosuppressants FK506 and D-allose on allogenic orthotopic liver transplantation in rats. 2000 Transplant. Proc. pmid:11120048
Ali MN et al. Case series: hemolytic uremic syndrome--another cause of transplant dysfunction. 2013 Transplant. Proc. pmid:24182801
Kliem V et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. 1999 Transplant. Proc. pmid:10576041
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Gonzalez-Molina M et al. Mycophenolate mofetil and tacrolimus reduce mortality after deceased donor kidney transplantation. 2012 Transplant. Proc. pmid:23146459
Batista F et al. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. 2012 Transplant. Proc. pmid:23146461
Yeung S et al. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. 2004 Transplant. Proc. pmid:15518754
Hu RH et al. Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression. 2004 Transplant. Proc. pmid:15518757
Alloway RR et al. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. 1996 Transplant. Proc. pmid:8623494
Dumont FJ et al. Up-regulation of gene expression by FK 506. 1991 Transplant. Proc. pmid:1721300
Woodle ES et al. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506. 1996 Transplant. Proc. pmid:8623495
Rao P et al. Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. 1991 Transplant. Proc. pmid:1721301
Curro G et al. Transient ischemic attack after rizatriptan administration in a liver transplant recipient: a case report. 2006 Transplant. Proc. pmid:17112920
Uchida H et al. Experimental intestinal transplantation using mouse fetal intestine in the rat: combination effect of FK 506 with cyclophosphamide. 1999 Transplant. Proc. pmid:10578297
Wasilewski G et al. Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen? 2014 Transplant. Proc. pmid:25380929
Jin KB et al. The production of reactive oxygen species in tacrolimus-treated glial cells. 2008 Transplant. Proc. pmid:18929834
Chung YW et al. Transcriptional activation of nuclear-related factor 2 by FK506 in Jurkat T cells. 2015 Transplant. Proc. pmid:25891728
Benedini S et al. Glucose and leucine metabolism in lung tranplanted patients on low dose of steroids for immunosuppressive therapy. 2008 Transplant. Proc. pmid:18589153
Takara T et al. Intraportal donor-specific transfusion given 24 hours before small bowel transplantation with cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7518150
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Borg AJ and Kumagai M FK 506 and xenogeneic human anti-porcine cellular reactivity. 1991 Transplant. Proc. pmid:1721332
Lladó L et al. Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy. 2002 Transplant. Proc. pmid:12176468
Serrano J et al. Tacrolimus is effective in both dual and triple regimens after liver transplantation. 2002 Transplant. Proc. pmid:12176469
Fleck PR et al. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. 1998 Transplant. Proc. pmid:9865299
du Toit DF et al. Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. 1998 Transplant. Proc. pmid:9865300
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Regazzi MB et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. 1997 Transplant. Proc. pmid:9142302
Hansen LJ et al. Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. 1997 Transplant. Proc. pmid:9142303
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Fukuhara N et al. Long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart-beating donors. 2002 Transplant. Proc. pmid:12176492
Barrera-Pulido L et al. Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. 2008 Transplant. Proc. pmid:19010156
Tanabe K et al. Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. 2002 Transplant. Proc. pmid:12176493
Gruttadauria S et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182762
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Gojowy D et al. High Frequency of Arterial Hypertension in Patients After Liver Transplantation. 2016 Transplant. Proc. pmid:27496479
Jordan ML et al. FK 506 conversion of renal allografts failing cyclosporine immunosuppression. 1991 Transplant. Proc. pmid:1721365
Wilusz M et al. Effects of Immunosuppressive Drugs on Serum Fatty Acids of Phospholipids Fraction in Renal Transplant Recipients. 2016 Transplant. Proc. pmid:27496457
Alessiani M et al. Infections in adult liver transplant patients under FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1703345
Yamauchi M et al. Effects of FK506 on rat thymic microenvironment in thymocyte maturation, proliferation, and mobilization. 1998 Transplant. Proc. pmid:9838578
Mueller AR et al. Is the use of marginal liver grafts justified? 1999 Feb-Mar Transplant. Proc. pmid:10083160
Miki T et al. Xenogeneic humoral graft-Vs-host disease following hamster-to-Rat bone marrow transplantation. 2000 Transplant. Proc. pmid:10936339
Zipperle S et al. Impaired T-cell IL-10 secretion and CD4 helper function in liver transplant patients treated with tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123208
Chien YS et al. Incidence and risk factors of new-onset diabetes mellitus after renal transplantation. 2008 Transplant. Proc. pmid:18790250
Moons P et al. Steroids may compromise quality of life of renal transplant recipients on a tacrolimus-based regimen. 2002 Transplant. Proc. pmid:12176538
Sharma A et al. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. 2008 Transplant. Proc. pmid:18790252
Sato K et al. Pancreaticoduodenal allotransplantation with cyclosporine and FK506. 1989 Transplant. Proc. pmid:2468212
Freise CE et al. Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. 1991 Transplant. Proc. pmid:1721397
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Gasser M et al. Putative regulatory function of alloreactive Th2 cells in tolerant recipients after small bowel transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11266759
Nakao A et al. Changes of allo-intestinal graft survival and intragraft cytokine expression by bone marrow augmentation with tacrolimus treatment in rats. 2001 Feb-Mar Transplant. Proc. pmid:11266851
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Alessiani M et al. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. 2000 Transplant. Proc. pmid:10995933
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Weir MR Optimizing early de novo immunosuppression with sirolimus. 2008 Transplant. Proc. pmid:19100903
Chang HR et al. Sirolimus addition is beneficial for renal allograft dysfunction due to simultaneous acute rejection episode and calcineurin inhibitor nephrotoxicity. 2004 Transplant. Proc. pmid:15621119
Khwaja K et al. Pancreas transplantation in cross-match-positive recipients using cyclosporine- or tacrolimus-based immunosuppression. 2002 Transplant. Proc. pmid:12176621
Fukuzawa M et al. Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. 1991 Transplant. Proc. pmid:1721427
Park KM et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. 1996 Transplant. Proc. pmid:8658863
Venkataramanan R et al. Biopharmaceutical aspects of FK-506. 1987 Transplant. Proc. pmid:2445070
Ishikawa S et al. Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report. 2018 Transplant. Proc. pmid:29661455
Chakrabarti P et al. Outcome after steroid withdrawal in adult renal transplant patients receiving tacrolimus-based immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267274
Fukuoka N et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. 2010 Transplant. Proc. pmid:20832577
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Maroun T et al. Rejection therapy with tacrolimus in renal transplantation: preliminary results of a collaborative multicenter study in 45 patients. Groupe Cooperatif de Transplantation D'ile de France (GCIF). 1998 Transplant. Proc. pmid:9745576
Pirsch JD Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. 1998 Transplant. Proc. pmid:9723448
Antoine C et al. Vascular microthrombosis in renal transplant recipients treated with tacrolimus. 1998 Transplant. Proc. pmid:9745577
Ito Y et al. Complete replacement of tracheal epithelia by the host promotes spontaneous acceptance of orthotopic tracheal allografts in rats. 2004 Transplant. Proc. pmid:15561264
Kiji T et al. Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts. 2004 Transplant. Proc. pmid:15561265
Fung JJ and Starzl TE FK 506 in solid organ transplantation. 1994 Transplant. Proc. pmid:7524226
McCauley J et al. FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. 1991 Transplant. Proc. pmid:1721459
Carrieri G et al. Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. 1991 Transplant. Proc. pmid:1721460
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Owen ER et al. Peripheral nerve regeneration in human hand transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267484
Ben-Ari Z et al. Conversion of liver allograft recipients from cyclosporine A to FK 506 immunosuppressive therapy. 2000 Transplant. Proc. pmid:10856553
Stempfle HU et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. 1998 Transplant. Proc. pmid:9636459
Wojciechowski D et al. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923623
Nanmoku K et al. Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923615
Ericzon BG et al. Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. 1991 Transplant. Proc. pmid:1703695